ABBV Today - Aug 11: $8 Billion Debt Deal
Impossibile aggiungere al carrello
Puoi avere soltanto 50 titoli nel carrello per il checkout.
Riprova più tardi
Riprova più tardi
Rimozione dalla Lista desideri non riuscita.
Riprova più tardi
Non è stato possibile aggiungere il titolo alla Libreria
Per favore riprova
Non è stato possibile seguire il Podcast
Per favore riprova
Esecuzione del comando Non seguire più non riuscita
-
Letto da:
-
Di:
A proposito di questo titolo
So, what’s the scoop? AbbVie just took on a whopping $8 billion in debt for its Apogee deal. Yeah, that one stung a bit for some folks. When you hear “debt,” it usually raises eyebrows, especially for dividend investors. People were wondering if this move might hurt their precious payouts down the line.
Now, here’s the thing. Some analysts are a bit worried about AbbVie’s earnings potential. Like, Erste Group Bank just lowered its EPS estimates for FY2027. That’s not exactly a warm hug for investors looking for growth. And to add to the mix, BNP Paribas adjusted their price target on AbbVie to $247, which is a bit of a bump up from where it was, but they’re still neutral on the stock. So, it’s like, they’re saying, “We see potential, but we’re not super excited about it.”
But don’t let that totally bring you down. AbbVie did post some strong Q2 earnings recently, which had some investors feeling a little more optimistic. It’s like they’re trying to balance the good with the not-so-good.
One thing worth knowing about is that this big debt deal might signal AbbVie’s plans to invest heavily in its pipeline. They’re all about growth, and sometimes you gotta take risks to get there. So, keep an eye on how they manage this debt and what it means for their future projects.
Alright, that’s the lowdown on AbbVie today! Remember, this is just for fun and info—no financial advice here. Catch you later!
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione